Journal of Clinical Oncology
Articles in this Issue
Role of ATM as a prognostic biomarker in non small cell lung cancer: A systematic review and meta-analysis.
e20543 Background: Non-small cell lung cancer (NSCLC) constitutes the majority of lung cancer diagnoses and remains associ...
Olanzapine for chemotherapy-related anorexia: Impact on body composition.
12065 Background: Chemotherapy-related anorexia and weight loss are associated with adverse outcomes in patients with adva...
Dynamics of tissue fatty acid profiles and association with radiotherapy toxicity in locally advanced nasopharyngeal carcinoma.
e18048 Background: Tissue levels of n-6 and n-3 fatty acids (FAs), reflected by erythrocyte membrane composition, modulate...
Quality of life in patients with gastroenteropancreatic neuroendocrine tumors receiving <sup>177</sup> Lu-edotreotide or everolimus: Results from the COMPETE study.
4171 Background: The Phase 3 COMPETE trial demonstrated a significant treatment effect in favor of 177...
Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.
3066 Background: Diagnosis and risk stratification of brain lesions is challenging when tissue biopsy is contraindicated d...
Overall survival analysis of eSyM: A cluster randomized trial of an electronic patient-reported outcomes (ePRO)-based symptom management program.
11003 Background: ePRO monitoring can improve outcomes yet remains underutilized in routine cancer care. We conducted a pr...
Age-related differences in patient burden in endometrial cancer: Findings from the international EXPRESSION XI/IMPROVE survey.
e17622 Background: Despite favourable survival in early-stage endometrial cancer (EC), patients experience a substantial d...
Magnitude and timing of clinical benefit associated with pathologic complete response in perioperative muscle-invasive bladder cancer: A reconstructed IPD analysis of NIAGARA trial.
4607 Background: Pathologic complete response (pCR) is widely used as an early efficacy endpoint in neoadjuvant or periope...
Racial and ethnic differences in melanoma survival in the era of immunotherapy.
e21588 Background: Since the introduction of immune checkpoint inhibitors (ICIs) in 2011, mortality in advanced melanoma h...
Immune profiling of tumor-infiltrating lymphocytes in patients with primary and metastatic soft tissue sarcomas.
e23544 Background: Soft tissue sarcomas (STSs) are rare and heterogeneous cancers with limited responsiveness to immune ch...
Clinical validation of a blood-based multimodal immune-response score in a real-world cohort of advanced non–small cell lung cancer.
e20581 Background: Immune checkpoint inhibitors (ICIs) have transformed care for advanced non-small cell lung cancer (aNSC...
A novel approach to improving clinical trial referral and enrollment for patients with cancer: A cross-sectional analysis.
e23310 Background: Participation in clinical trials is fundamental to advancements in cancer treatment. Recent data estima...
Clinical impact of pulmonary embolism in hospitalized patients with breast cancer: A National Inpatient Sample analysis.
e22623 Background: Pulmonary embolism (PE) is a serious thromboembolic complication in hospitalized patients with malignan...
Machine learning–based transcriptomic signatures to predict treatment outcomes across targeted and immunotherapy regimens in renal cell carcinoma.
4526 Background: Despite available tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), reliable bio...
Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial.
e15583 Background: Despite established first- and second-line standards with chemotherapy plus anti-VEGF or anti-EGFR agen...
Efficacy and safety of transarterial chemoembolization combined with donafenib for hepatocellular carcinoma with rupture and bleeding: A retrospective, cohort study.
4107 Background: The incidence of hepatocellular carcinoma (HCC) ranks 6th in the world, and rupture and bleeding of HCC i...
Association between selective serotonin reuptake inhibitor use and outcomes in metastatic melanoma treated with immune checkpoint inhibitors: A real-world cohort study.
11188 Background: Immune checkpoint inhibitors (ICIs) have transformed outcomes for metastatic melanoma, yet substantial v...
ctDNA for monitoring disease status in HPV-negative head and neck cancer in an underserved population.
e18035 Background: Head and neck squamous cell carcinoma (HNSCC) is clinically heterogeneous with significant morbidity an...
PD-L1 score: Tool effectiveness in non-small cell lung cancer.
e20594 Background: Programmed death (and ligand)-1 (PD-(L)1) inhibitors are standard of care for treatment of non-small ce...
TME-informed bioprinted 3D tissue model as used to characterize architecture-associated drug uptake and response in PDAC.
4220 Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumors despite extensive drug...
Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy.
TPS643 Background: Treatment for stage II-III triple negative breast cancer (TNBC) uses neoadjuvant chemoimmunotherapy (NC...
GLP-1 receptor agonists vs 5-alpha reductase inhibitors for prostate cancer primary prevention in high-risk men: A real-world head-to-head comparison.
e17134 Background: Despite being the most prevalent malignancy among men, prostate cancer (PC) lacks FDA-approved primary...
Association of baseline vitamin D levels with survival and disease control in diffuse large B-cell lymphoma: A meta-analysis.
e19082 Background: Vitamin D enhances antibody-dependent cellular cytotoxicity, a key mechanism underlying anti-CD20 monoc...
Impact of FES-PET imaging in the management of estrogen receptor–positive breast cancer: Real-world experience.
1080 Background: F18 labeled estradiol PET imaging (FES-PET) is endorsed by NCCN guidelines to identify advanced/recurrent...
Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
4504 Background: Immune checkpoint inhibitors have a defined role peri-operatively and in the adjuvant setting when cystec...